Evidence map›Paper›PMID 42102209›Full record

ArticleScience advances2026

Drp1 regulates mitochondrial health and controls skeletal muscle mass through the Erk1/2-Nur77 pathway.

Alice M Ma, Peter H Tran, Nicole L Yang, Jennifer Ngo, Hirotaka Iwasaki, Wenjuan Ren, Simone Livit, Linsey Stiles, Sarah Wang, Trinity Ho and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Alice M MaDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0009-0002-8777-8044
Peter H TranDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-4467-2055
Nicole L YangDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-6684-7939
Jennifer NgoDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-5829-6866
Hirotaka IwasakiDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-0528-4263
Wenjuan RenDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Simone LivitDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Linsey StilesDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Sarah WangDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0009-0005-5190-2332
Trinity HoDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Emma Y YimDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Noelle MorrowDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-7015-4273
Morgan M JohnsonDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-0174-7670
Caroline ClearyDivision of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kai ZouDepartment of Exercise and Health Sciences, University of Massachusetts Boston, Boston, MA 02125, USA.ORCID 0000-0003-4164-7129
Rachelle H CrosbieDepartment of Integrative Biology and Physiology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Yuwei JiangDepartment of Physiology and Biophysics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.ORCID 0000-0002-5082-8012
Orian S ShirihaiDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-8466-3431
Jonathan WanagatDivision of Geriatrics, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0002-8460-8616
Sushil MahataVA San Diego Healthcare System, San Diego, CA 92161, USA.ORCID 0000-0002-9154-0787
James A WohlschlegelDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-3399-901X
Andrea L HevenerDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-1508-4377
Zhenqi ZhouDivision of Endocrinology, Diabetes and Hypertension, Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0001-6560-9704

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The maintenance of skeletal muscle mass relies on mitochondrial quality control, including balanced dynamics and mitophagy. Dynamin-related protein 1 (Drp1), a central mediator of mitochondrial fission, is essential for these processes, yet its role in muscle mass regulation remains incompletely defined. Here, we show that acute Drp1 deletion in the skeletal muscle increases Parkin-mediated mitochondrial degradation, reduces mitochondrial DNA (mtDNA) content, and leads to severe muscle atrophy. Although dual deletion of Drp1 and Parkin restores mtDNA content, muscle loss persists. Mechanistically, Drp1 loss impairs mitochondrial respiratory chain activity, suppressing extracellular signal-regulated kinase 1/2 (Erk1/2) signaling and down-regulating the nuclear receptor subfamily 4 group A member 1 (Nur77). Pharmacologic β2-adrenergic receptor activation with clenbuterol reactivated Erk1/2, restored Nur77 expression, and rescued muscle atrophy. These findings define a Drp1-Erk1/2-Nur77 signaling axis linking mitochondrial integrity to skeletal muscle mass and identify a potential therapeutic target for muscle degeneration in mitochondrial and metabolic diseases.

Indexed as

DynaminsMAP Kinase Signaling SystemMitochondriaMuscle, SkeletalNuclear Receptor Subfamily 4, Group A, Member 1AnimalsDNA, MitochondrialMiceMitogen-Activated Protein Kinase 3Muscular AtrophySignal TransductionDNA, MitochondrialDnm1l protein, mouseDynaminsMitogen-Activated Protein Kinase 3Nr4a1 protein, mouseNuclear Receptor Subfamily 4, Group A, Member 1

Identifiers

PMID42102209
PMCPMC13155292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.